Assignee
INCYTE CORP
US·593 granted patents·363 pending applications·8,575 citations·filing 1995–2025
Top patents by PatentIndex Score
956 records- 0199US11566026B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jan 31, 2023·16 cites·19 claims
- 0299US11331320B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitorsINCYTE CORP·Filed 2020·Granted May 17, 2022·12 cites·21 claims
- 0399US11285140B2Piperidin-4-yl azetidine derivatives as JAK1 inhibitorsINCYTE CORP·Filed 2020·Granted Mar 29, 2022·14 cites·2 claims
- 0499US11059821B21H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteinsINCYTE CORP·Filed 2020·Granted Jul 13, 2021·13 cites·26 claims
- 0599US10639310B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitorsINCYTE CORP·Filed 2018·Granted May 5, 2020·20 cites·6 claims
- 0699US10398699B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitorsINCYTE CORP·Filed 2018·Granted Sep 3, 2019·31 cites·7 claims
- 0799US9974790B2Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitorsINCYTE CORP·Filed 2016·Granted May 22, 2018·40 cites·14 claims
- 0899US9938294B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2017·Granted Apr 10, 2018·24 cites·14 claims
- 0999US9624241B2Tricyclic heterocycles as BET protein inhibitorsINCYTE CORP·Filed 2015·Granted Apr 18, 2017·27 cites·8 claims
- 1099US9623029B23-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitorsINCYTE CORP·Filed 2015·Granted Apr 18, 2017·44 cites·11 claims
- 1199US9181271B2Tricyclic fused thiophene derivatives as JAK inhibitorsINCYTE CORP·Filed 2013·Granted Nov 10, 2015·105 cites·6 claims
- 1299US9079912B2Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitorsINCYTE CORP·Filed 2014·Granted Jul 14, 2015·75 cites·6 claims
- 1399US8829013B1Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE CORP·Filed 2014·Granted Sep 9, 2014·91 cites·14 claims
- 1499US8822481B1Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE CORP·Filed 2014·Granted Sep 2, 2014·89 cites·28 claims
- 1599US8722693B2Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrileINCYTE CORP·Filed 2013·Granted May 13, 2014·143 cites·10 claims
- 1699US8053433B2Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitorsINCYTE CORP·Filed 2007·Granted Nov 8, 2011·107 cites·15 claims
- 1799US7767675B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2007·Granted Aug 3, 2010·85 cites·85 claims
- 1899US7598257B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitorsINCYTE CORP·Filed 2006·Granted Oct 6, 2009·328 cites·8 claims
- 1999US7335667B2Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitorsINCYTE CORP·Filed 2005·Granted Feb 26, 2008·149 cites·38 claims
- 2099US6645499B1Human ena/VASP-like protein splice variantINCYTE CORP·Filed 1999·Granted Nov 11, 2003·211 cites·2 claims
- 2198US12084443B2Process of preparing a PD-1/PD-L1 inhibitorINCYTE CORP·Filed 2023·Granted Sep 10, 2024·5 cites·9 claims
- 2298US11866435B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Granted Jan 9, 2024·7 cites·21 claims
- 2398US11787793B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Granted Oct 17, 2023·9 cites·25 claims
- 2498US11760756B2Crystalline form of a PD-1/PD-L1 inhibitorINCYTE CORP·Filed 2021·Granted Sep 19, 2023·9 cites·46 claims
- 2598US11753406B2Salts of a PD-1/PD-L1 inhibitorINCYTE CORP·Filed 2020·Granted Sep 12, 2023·9 cites·23 claims
- 2698US11718605B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 8, 2023·11 cites·28 claims
- 2798US11673883B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·12 cites·29 claims
- 2898US11613536B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2021·Granted Mar 28, 2023·15 cites·15 claims
- 2998US11608337B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Mar 21, 2023·15 cites·22 claims
- 3098US11572366B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Feb 7, 2023·15 cites·28 claims
- 3198US11530214B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Dec 20, 2022·7 cites·26 claims
- 3298US11465981B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Oct 11, 2022·18 cites·28 claims
- 3398US11414433B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 16, 2022·23 cites·50 claims
- 3498US11407749B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 9, 2022·23 cites·24 claims
- 3598US11401279B2Pyrido[3,2-d]pyrimidine compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 2, 2022·24 cites·14 claims
- 3698US11339149B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted May 24, 2022·24 cites·20 claims
- 3798US11173162B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2020·Granted Nov 16, 2021·22 cites·19 claims
- 3898US11124511B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Sep 21, 2021·28 cites·35 claims
- 3998US11104682B2Salts of TAM inhibitorsINCYTE CORP·Filed 2020·Granted Aug 31, 2021·7 cites·35 claims
- 4098US11066394B2Solid forms of an HPK1 inhibitorINCYTE CORP·Filed 2020·Granted Jul 20, 2021·12 cites·44 claims
- 4198US11053246B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Jul 6, 2021·23 cites·10 claims
- 4298US11014923B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2020·Granted May 25, 2021·22 cites·32 claims
- 4398US10947230B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2019·Granted Mar 16, 2021·26 cites·44 claims
- 4498US10906920B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Feb 2, 2021·29 cites·41 claims
- 4598US10813930B2Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3INCYTE CORP·Filed 2019·Granted Oct 27, 2020·27 cites·42 claims
- 4698US10800768B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 13, 2020·30 cites·18 claims
- 4798US10793565B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 6, 2020·27 cites·16 claims
- 4898US10738048B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Aug 11, 2020·28 cites·21 claims
- 4998US10669271B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Jun 2, 2020·40 cites·20 claims
- 5098US10632126B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Apr 28, 2020·27 cites·8 claims
Showing the top 50 of 956 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →